Medical Devices Africa

Africa Liquid Biopsy Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Africa Liquid Biopsy Market Industry Trends and Forecast to 2034: Segmented by (Biomarker, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Africa · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $108.6 Mn Placeholder estimate
Estimate 2025 $128.9 Mn 1.4% of the global market
Projected 2034 $603.1 Mn 367.8% Adds $474.2 Mn over 9 forecast years
CAGR 2025–2034 18.7% Faster than 90% of 173 Medical Devices markets here
Key players 6 +1
  • Africa is 1.45% of the global market.
  • Among regions, the largest is North America at $4.10 Bn.
  • Fastest growing: Africa (this report) at 18.7% a year.
  • Africa ranks 6th of 6 by size among regions.

Market size projection

Africa

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$474.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Liquid Biopsy Market market size by year, Africa
YearMarket sizeChange that yearSince 2025
2024 (estimate) $108.6 Mn — —
2025 (base) $128.9 Mn +$20.3 Mn —
2026 (forecast) $153.0 Mn +$24.1 Mn +18.7%
2027 (forecast) $181.6 Mn +$28.6 Mn +40.9%
2028 (forecast) $215.6 Mn +$34.0 Mn +67.2%
2029 (forecast) $255.9 Mn +$40.3 Mn +98.5%
2030 (forecast) $303.8 Mn +$47.9 Mn +135.6%
2031 (forecast) $360.6 Mn +$56.8 Mn +179.7%
2032 (forecast) $428.0 Mn +$67.4 Mn +232%
2033 (forecast) $508.1 Mn +$80.0 Mn +294.1%
2034 (forecast) $603.1 Mn +$95.0 Mn +367.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Africa Liquid Biopsy Market Analysis at a glance
Market size, 2025$128.9 Mn placeholder estimate
Forecast, 2034$603.1 Mn placeholder estimate
Growth (CAGR), 2025–203418.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsBiomarker, application and end user (see all)
Key playersGuardant Health, Inc., Roche, GRAIL, Natera, Exact Sciences Corporation and 1 more (see all)
Regulator in AfricaAMASource: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
Active clinical trials1 in AfricaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Africa Liquid Biopsy Market Analysis Executive Summary

Liquid biopsy finds cancer signals such as tumour DNA in a blood sample, to detect cancer, guide treatment and check for relapse.

Key segments of the liquid Biopsy market include biomarker (Circulating Tumor DNA, Circulating Tumor Cells and Exosomes) and application (Treatment Selection, Recurrence Monitoring and Early Detection).

Bar chart: Africa Liquid Biopsy market size, 2024–2034, placeholder estimates. $108.6 Mn in 2024, $128.9 Mn in 2025 and $603.1 Mn in 2034, 18.7% CAGR.
Africa Liquid Biopsy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Africa Liquid Biopsy Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the liquid Biopsy market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the liquid Biopsy market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the liquid Biopsy market, especially in low- and middle-income countries.

Competitive Landscape for Liquid Biopsy Market in Africa

The liquid Biopsy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Liquid Biopsy Market in Africa

Liquid Biopsy in Africa: rules, payment and research

The African Medicines Agency (AMA) treaty covers medical devices and diagnostics as well as medicines; national regulators still approve products.⁠[1] In some of the countries we cover here, medical devices are regulated by EDA (Egypt)⁠[2], PPB (Kenya)⁠[3] and SAHPRA (South Africa)⁠[4]. How care is paid for in some of these countries: universal health insurance (Egypt)⁠[5], the SHA (Kenya)⁠[6] and planned National Health Insurance (South Africa)⁠[7]. ClinicalTrials.gov lists 1 study on Liquid Biopsy that is recruiting, active or about to start in Africa.⁠[8]

[1] African Union, African Medicines Agency treaty. Checked 14 Nov 2026.

[2] Egyptian Drug Authority. Checked 14 Nov 2026.

[3] Pharmacy and Poisons Board. Checked 14 Nov 2026.

[4] South African Health Products Regulatory Authority. Checked 14 Nov 2026.

[5] Universal Health Insurance Authority. Checked 14 Nov 2026.

[6] Social Health Authority. Checked 14 Nov 2026.

[7] National Department of Health. Checked 14 Nov 2026.

[8] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how liquid Biopsy products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Africa.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Liquid Biopsy right now, from free public sources.

Clinical trials

1 active trial in Egypt, South Africa, Kenya, Nigeria, Ethiopia, DR Congo, Uganda, Tanzania, Niger, Mozambique, Sudan, Malawi, Zambia, Mali, Burkina Faso, Ghana and Morocco

Recruiting, about to start, or running now. Counted across the 17 countries we report on in Africa.

Top trial sponsors (worldwide)

  1. Epiliquid Holding, Inc 3 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Gene Solutions 3 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Tethis S.p.A. 2 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Guardant Health, Inc. 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Liquid Biopsy in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Liquid Biopsy market in Africa?
Placeholder estimate: about $128.9 Mn in 2025, rising to about $603.1 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Liquid Biopsy market in Africa growing?
Placeholder estimate: about 18.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Liquid Biopsy market report cover?
The report splits the market by biomarker (Circulating Tumor DNA, Circulating Tumor Cells, Exosomes), application (Treatment Selection, Recurrence Monitoring, Early Detection) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Liquid Biopsy market?
Key players include Guardant Health, Inc., Roche, GRAIL, Natera, Exact Sciences Corporation and Illumina, Inc..
What is driving the Liquid Biopsy market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the liquid Biopsy market. Faster approvals and new combinations are improving survival.
Who regulates Liquid Biopsy in Africa?
The African Medicines Agency (AMA) treaty covers medical devices and diagnostics as well as medicines; national regulators still approve products. Source: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
How many clinical trials on Liquid Biopsy are running in Africa?
1 study is recruiting, active or about to start in Africa, counted across the 17 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
How much research is published on Liquid Biopsy?
PubMed lists 10,752 papers on Liquid Biopsy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Africa

See all

Related on oncology and diagnostics and lab testing

See the topic